Leveraging Genomics and Big Data to Deliver Precise, Personalized Medicine

AMPEL BioSolutions was founded in 2013, by Dr Peter Lipsky and Dr Amrie Grammer, to bring precision medicine to individual patients, especially those suffering from lupus. We are focused on the transformative process to target, identify, and hasten development of treatments for autoimmune and inflammatory diseases. The AMPEL team brings their expertise in basic and translational research, clinical trial design, and bioinformatics together in a new way to develop scalable systems using AI and deep machine learning to improve patient outcomes.